Swipe Left For English News
上海,
2026年4月17日
全球领先的合同研究、开发和生产（CRDMO）服务公司药明生物（WuXi Biologics, 2269.HK）宣布公司获评2026年度晨星Sustainalytics“行业ESG领导者”和“区域ESG领导者”。
这是药明生物第六年获得该项认可，不仅体现了公司在全球业务运营及价值链各环节中大力推进可持续发展的长期实践与显著成果，也进一步明确了其持续深化绿色CRDMO的长期发展目标。
晨星Sustainalytics作为知名ESG研究、评级及分析机构，致力于为投资者制定和实施负责任投资策略提供专业支持。其2026年ESG风险评级覆盖全球42个行业、约15000家企业，基于行业及区域的同业对比评出ESG领导者，以表彰企业的优秀风险管理能力和卓越ESG表现。早在2025年7月，药明生物获Sustainalytics评定为“可忽略风险”最高等级，跻身全球参评企业前1%。
陈智胜
博士
药明生物首席执行官
ESG委员会主席
我们非常荣幸再次获得晨星Sustainalytics的认可。通过持续加快生物药从分子到患者的进程，药明生物赋能全球客户提升创新生物药的可及性与可负担性，为推动全球医疗公平与改善公共健康贡献长期价值。同时，作为可持续发展领域的领导者，我们与各利益相关方协同合作，积极创造社会与环境影响，通过端到端绿色CRDMO解决方案赋能全球客户，推动整个价值链负责任发展。
过去数年，药明生物在可持续发展领域的持续投入，获得多家国际权威 ESG 评级机构认可，包括MSCI ESG最高AAA评级、EcoVadis铂金奖章、入选标普道琼斯领先指数（原标普道琼斯可持续发展指数）、CDP气候变化、水安全和供应商合作评估三大领域A级榜单、入选富时社会责任指数、ISS ESG “最佳”评级、入选恒生可持续发展企业基准指数。
关于药明生物
药明生物（股票代码：2269.HK）是一家全球领先的合同研究、开发和生产(CRDMO)公司。公司通过开放式、一体化生物制药能力和技术赋能平台，提供全方位的端到端服务，帮助合作伙伴发现、开发及生产生物药，实现从概念到商业化生产的全过程，加速全球生物药研发进程，降低研发成本，造福全球病患。
依托连结中国、美国、爱尔兰、德国和新加坡的全球网络，药明生物汇聚逾13000名员工，包括在生物药研发及生产、技术创新和卓越运营等领域的行业专家与科学家。公司凭借领先的技术平台和精深的专业能力，为客户提供高效、成本优势、规模化的生物药解决方案，精准满足不同阶段的客户需求。此外，公司还将数字化能力与基础设施系统性嵌入生物药研发、实验室运营与生产制造的全价值链，把数据、计算与预测能力转化为更透明的客户合作体验、更快的研发进程、更智能的运营管理与更高效的生产交付。截至2025年12月底，药明生物帮助客户研发和生产的综合项目高达945个，其中包括74个临床III期项目，25个商业化生产项目，复杂分子项目合计占比超过公司总项目数50%。
药明生物以可持续发展为长期业务增长的基石。公司持续推动绿色创新技术，为全球合作伙伴提供先进的端到端绿色CRDMO解决方案，同时在ESG方面不断取得卓越成就。秉承创造共享价值的理念，公司携手利益相关方构建可持续发展生态，通过负责任运营模式推动社会价值与生态效益双提升，实现全价值链的协同赋能。
更多信息，请访问：www.wuxibiologics.com。
ESG
esg@wuxibiologics.com
媒体关系
PR@wuxibiologics.com
WuXi Biologics Recognized by Morningstar Sustainalytics as Industry and Regional ESG Leader for Sixth Year
Shanghai,
April 17, 2026
WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has been named by Morningstar Sustainalytics as both an Industry ESG Leader and a Regional ESG Leader for 2026.
Marking the sixth consecutive year that WuXi Biologics has received this honor, the recognition highlights the company's unwavering commitment to advancing sustainability throughout its global business operations and value chain, and demonstrates the success of its long-term sustainability strategy and its vision as a Green CRDMO leader.
Morningstar Sustainalytics is a leading independent ESG research, ratings, and analytics provider supporting global investors in the development and implementation of responsible investment strategies. Its 2026 ESG Risk Ratings assessed around 15,000 companies worldwide across 42 industries, with ESG Leader distinctions awarded to companies demonstrating robust ESG risk management and performance relative to their peers across industries and regions. In July 2025, WuXi Biologics was also placed in Sustainalytics' highest ESG rating tier of negligible risk, achieving a top 1% global ranking score.
Dr. Chris Chen
Chief Executive Officer
Chairman of the ESG Committee
WuXi Biologics
We are honored to once again be recognized by Morningstar Sustainalytics. As a proactive leader in sustainability, we are committed to collaborating with all stakeholders to create positive social and environmental impacts, empowering our global clients through end-to-end Green CRDMO solutions, and advancing responsible practices across the entire value chain. In addition, we drive equal availability and affordability to innovative therapeutics worldwide by accelerating the journey from molecules to market, and enabling innovative biologics to reach patients faster, at greater scale, and with consistent quality.
Over the years, WuXi Biologics' consistent efforts to promote sustainable development have received notable recognition from leading global ESG rating agencies, including an MSCI AAA Rating; an EcoVadis Platinum Medal; a listing in the Dow Jones Best-in-Class Indices (formerly Dow Jones Sustainability Indices); CDP "A List" status for Climate Change, Water Security, and Supplier Engagement Assessment; inclusion in the FTSE4Good Index Series; a "Prime" designation from ISS ESG Rating; and inclusion in the Hang Seng Corporate Sustainability Benchmark Index.
About
WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 13,000 employees in China, the United States, Ireland, Germany, and Singapore — including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence — WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients’ needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of December 31, 2025, WuXi Biologics is supporting 945 integrated client projects, including 74 in Phase III and 25 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com
Contacts
ESG
esg@wuxibiologics.com
Media
PR@wuxibiologics.com
注：本信息不构成药明生物的信息披露或投资建议
请点击右下角【爱心】，
并将公众号设为【星标】，
第一时间收到药明生物最新消息
